Global Cardiovascular Disease Drugs Market Size, Status and Forecast 2022

August 2017 | 106 pages | ID: G4C5DAF9E43EN
QYResearch

Abstracts

This report studies the global Cardiovascular Disease Drugs market, analyzes and researches the Cardiovascular Disease Drugs development status and forecast in United States, EU, Japan, China, India and Southeast Asia.
This report focuses on the top players in global market, like

• AstraZeneca
• Johnson＆Johnson
• Pfizer
• Sanofi
• Merck
• Daiichi Sankyo Company Limited
• Novartis
• Bayer
• Takeda Pharmaceutical
• Hoffmann-La Roche
• United Therapeutics Corporation
• Actelion Pharmaceuticals
• Boehringer Ingelheim
• Astellas Pharma

Market segment by Regions/Countries, this report covers

• United States
• EU
• Japan
• China
• India
• Southeast Asia

Market segment by Type, Cardiovascular Disease Drugs can be split into

• Heparin
• Coumadin
• Sectral
• Zebeta
• Lopressor
• Toprol XL
• Norvasc
• Lotrel
• Others

Market segment by Application, Cardiovascular Disease Drugs can be split into

• Asischemic Heart Disease
• Dyslipidemia
• Stroke
• Thrombosis
• Atherosclerosis
• Coronary Artery Diseases
• Peripheral Artery Disease
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

Global Cardiovascular Disease Drugs Market Size, Status and Forecast 2022

1 INDUSTRY OVERVIEW OF CARDIOVASCULAR DISEASE DRUGS

1.1 Cardiovascular Disease Drugs Market Overview
  1.1.1 Cardiovascular Disease Drugs Product Scope
  1.1.2 Market Status and Outlook
1.2 Global Cardiovascular Disease Drugs Market Size and Analysis by Regions
  1.2.1 United States
  1.2.2 EU
  1.2.3 Japan
  1.2.4 China
  1.2.5 India
  1.2.6 Southeast Asia
1.3 Cardiovascular Disease Drugs Market by Type
  1.3.1 Heparin
  1.3.2 Coumadin
  1.3.3 Sectral
  1.3.4 Zebeta
  1.3.5 Lopressor
  1.3.6 Toprol XL
  1.3.7 Norvasc
  1.3.8 Lotrel
  1.3.9 Others
1.4 Cardiovascular Disease Drugs Market by End Users/Application
  1.4.1 Asischemic Heart Disease
  1.4.2 Dyslipidemia
  1.4.3 Stroke
  1.4.4 Thrombosis
  1.4.5 Atherosclerosis
  1.4.6 Coronary Artery Diseases
  1.4.7 Peripheral Artery Disease
  1.4.8 Others

2 GLOBAL CARDIOVASCULAR DISEASE DRUGS COMPETITION ANALYSIS BY PLAYERS

2.1 Cardiovascular Disease Drugs Market Size (Value) by Players (2016 and 2017)
2.2 Competitive Status and Trend
  2.2.1 Market Concentration Rate
  2.2.2 Product/Service Differences
  2.2.3 New Entrants
  2.2.4 The Technology Trends in Future

3 COMPANY (TOP PLAYERS) PROFILES

3.1 AstraZeneca
  3.1.1 Company Profile
  3.1.2 Main Business/Business Overview
  3.1.3 Products, Services and Solutions
  3.1.4 Cardiovascular Disease Drugs Revenue (Value) (2012-2017)
  3.1.5 Recent Developments
3.2 Johnson＆Johnson
  3.2.1 Company Profile
  3.2.2 Main Business/Business Overview
  3.2.3 Products, Services and Solutions
  3.2.4 Cardiovascular Disease Drugs Revenue (Value) (2012-2017)
  3.2.5 Recent Developments
3.3 Pfizer
  3.3.1 Company Profile
  3.3.2 Main Business/Business Overview
  3.3.3 Products, Services and Solutions
  3.3.4 Cardiovascular Disease Drugs Revenue (Value) (2012-2017)
  3.3.5 Recent Developments
3.4 Sanofi
  3.4.1 Company Profile
  3.4.2 Main Business/Business Overview
  3.4.3 Products, Services and Solutions
  3.4.4 Cardiovascular Disease Drugs Revenue (Value) (2012-2017)
  3.4.5 Recent Developments
3.5 Merck
  3.5.1 Company Profile
  3.5.2 Main Business/Business Overview
  3.5.3 Products, Services and Solutions
  3.5.4 Cardiovascular Disease Drugs Revenue (Value) (2012-2017)
  3.5.5 Recent Developments
3.6 Daiichi Sankyo Company Limited
  3.6.1 Company Profile
  3.6.2 Main Business/Business Overview
  3.6.3 Products, Services and Solutions
  3.6.4 Cardiovascular Disease Drugs Revenue (Value) (2012-2017)
  3.6.5 Recent Developments
3.7 Novartis
  3.7.1 Company Profile
  3.7.2 Main Business/Business Overview
  3.7.3 Products, Services and Solutions
  3.7.4 Cardiovascular Disease Drugs Revenue (Value) (2012-2017)
  3.7.5 Recent Developments
3.8 Bayer
  3.8.1 Company Profile
  3.8.2 Main Business/Business Overview
  3.8.3 Products, Services and Solutions
  3.8.4 Cardiovascular Disease Drugs Revenue (Value) (2012-2017)
  3.8.5 Recent Developments
3.9 Takeda Pharmaceutical
  3.9.1 Company Profile
  3.9.2 Main Business/Business Overview
  3.9.3 Products, Services and Solutions
  3.9.4 Cardiovascular Disease Drugs Revenue (Value) (2012-2017)
  3.9.5 Recent Developments
3.10 Hoffmann-La Roche
  3.10.1 Company Profile
  3.10.2 Main Business/Business Overview
  3.10.3 Products, Services and Solutions
  3.10.4 Cardiovascular Disease Drugs Revenue (Value) (2012-2017)
  3.10.5 Recent Developments
3.11 United Therapeutics Corporation
3.12 Actelion Pharmaceuticals
3.13 Boehringer Ingelheim
3.14 Astellas Pharma

4 GLOBAL CARDIOVASCULAR DISEASE DRUGS MARKET SIZE BY TYPE AND APPLICATION (2012-2017)

4.1 Global Cardiovascular Disease Drugs Market Size by Type (2012-2017)
4.2 Global Cardiovascular Disease Drugs Market Size by Application (2012-2017)
4.3 Potential Application of Cardiovascular Disease Drugs in Future
4.4 Top Consumer/End Users of Cardiovascular Disease Drugs

5 UNITED STATES CARDIOVASCULAR DISEASE DRUGS DEVELOPMENT STATUS AND OUTLOOK

5.1 United States Cardiovascular Disease Drugs Market Size (2012-2017)
5.2 United States Cardiovascular Disease Drugs Market Size and Market Share by Players (2016 and 2017)

6 EU CARDIOVASCULAR DISEASE DRUGS DEVELOPMENT STATUS AND OUTLOOK

6.1 EU Cardiovascular Disease Drugs Market Size (2012-2017)
6.2 EU Cardiovascular Disease Drugs Market Size and Market Share by Players (2016 and 2017)

7 JAPAN CARDIOVASCULAR DISEASE DRUGS DEVELOPMENT STATUS AND OUTLOOK

7.1 Japan Cardiovascular Disease Drugs Market Size (2012-2017)
7.2 Japan Cardiovascular Disease Drugs Market Size and Market Share by Players (2016 and 2017)

8 CHINA CARDIOVASCULAR DISEASE DRUGS DEVELOPMENT STATUS AND OUTLOOK

8.1 China Cardiovascular Disease Drugs Market Size (2012-2017)
8.2 China Cardiovascular Disease Drugs Market Size and Market Share by Players (2016 and 2017)

9 INDIA CARDIOVASCULAR DISEASE DRUGS DEVELOPMENT STATUS AND OUTLOOK

9.1 India Cardiovascular Disease Drugs Market Size (2012-2017)
9.2 India Cardiovascular Disease Drugs Market Size and Market Share by Players (2016 and 2017)

10 SOUTHEAST ASIA CARDIOVASCULAR DISEASE DRUGS DEVELOPMENT STATUS AND OUTLOOK

10.1 Southeast Asia Cardiovascular Disease Drugs Market Size (2012-2017)
10.2 Southeast Asia Cardiovascular Disease Drugs Market Size and Market Share by Players (2016 and 2017)

11 MARKET FORECAST BY REGIONS, TYPE AND APPLICATION (2017-2022)

11.1 Global Cardiovascular Disease Drugs Market Size (Value) by Regions (2017-2022)
  11.1.1 United States Cardiovascular Disease Drugs Revenue and Growth Rate (2017-2022)
  11.1.2 EU Cardiovascular Disease Drugs Revenue and Growth Rate (2017-2022)
  11.1.3 Japan Cardiovascular Disease Drugs Revenue and Growth Rate (2017-2022)
  11.1.4 China Cardiovascular Disease Drugs Revenue and Growth Rate (2017-2022)
  11.1.5 India Cardiovascular Disease Drugs Revenue and Growth Rate (2017-2022)
  11.1.6 Southeast Asia Cardiovascular Disease Drugs Revenue and Growth Rate (2017-2022)
11.2 Global Cardiovascular Disease Drugs Market Size (Value) by Type (2017-2022)
11.3 Global Cardiovascular Disease Drugs Market Size by Application (2017-2022)

12 CARDIOVASCULAR DISEASE DRUGS MARKET DYNAMICS

12.1 Cardiovascular Disease Drugs Market Opportunities
12.2 Cardiovascular Disease Drugs Challenge and Risk
  12.2.1 Competition from Opponents
  12.2.2 Downside Risks of Economy
12.3 Cardiovascular Disease Drugs Market Constraints and Threat
  12.3.1 Threat from Substitute
  12.3.2 Government Policy
  12.3.3 Technology Risks
12.4 Cardiovascular Disease Drugs Market Driving Force
  12.4.1 Growing Demand from Emerging Markets
  12.4.2 Potential Application

13 MARKET EFFECT FACTORS ANALYSIS

13.1 Technology Progress/Risk
  13.1.1 Substitutes
  13.1.2 Technology Progress in Related Industry
13.2 Consumer Needs Trend/Customer Preference
13.3 External Environmental Change
  13.3.1 Economic Fluctuations
  13.3.2 Other Risk Factors

14 RESEARCH FINDING/CONCLUSION

15 APPENDIX

Methodology
Analyst Introduction
Data Source

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Cardiovascular Disease Drugs Product Scope
Figure Global Cardiovascular Disease Drugs Market Size (Million USD) (2012-2017)
Table Global Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure Global Cardiovascular Disease Drugs Market Share by Regions in 2016
Figure United States Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure EU Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure Japan Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure China Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure India Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure Southeast Asia Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Figure Global Cardiovascular Disease Drugs Market Share by Type in 2016
Figure Heparin Market Size (Million USD) and Growth Rate (2012-2017)
Figure Coumadin Market Size (Million USD) and Growth Rate (2012-2017)
Figure Sectral Market Size (Million USD) and Growth Rate (2012-2017)
Figure Zebeta Market Size (Million USD) and Growth Rate (2012-2017)
Figure Lopressor Market Size (Million USD) and Growth Rate (2012-2017)
Figure Toprol XL Market Size (Million USD) and Growth Rate (2012-2017)
Figure Norvasc Market Size (Million USD) and Growth Rate (2012-2017)
Figure Lotrel Market Size (Million USD) and Growth Rate (2012-2017)
Figure Others Market Size (Million USD) and Growth Rate (2012-2017)
Figure Global Cardiovascular Disease Drugs Market Share by Application in 2016
Table Key Downstream Customer in Asischemic Heart Disease
Figure Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate in Asischemic Heart Disease (2012-2017)
Table Key Downstream Customer in Dyslipidemia
Figure Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate in Dyslipidemia (2012-2017)
Table Key Downstream Customer in Stroke
Figure Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate in Stroke (2012-2017)
Table Key Downstream Customer in Thrombosis
Figure Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate in Thrombosis (2012-2017)
Table Key Downstream Customer in Atherosclerosis
Figure Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate in Atherosclerosis (2012-2017)
Table Key Downstream Customer in Coronary Artery Diseases
Figure Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate in Coronary Artery Diseases (2012-2017)
Table Key Downstream Customer in Peripheral Artery Disease
Figure Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate in Peripheral Artery Disease (2012-2017)
Table Key Downstream Customer in Others
Figure Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate in Others (2012-2017)
Table Cardiovascular Disease Drugs Market Size (Million USD) by Players (2016 and 2017)
Figure Cardiovascular Disease Drugs Market Size Share by Players in 2016
Figure Cardiovascular Disease Drugs Market Size Share by Players in 2017
Table AstraZeneca Basic Information List
Table Cardiovascular Disease Drugs Business Revenue (Million USD) of AstraZeneca (2012-2017)
Figure AstraZeneca Cardiovascular Disease Drugs Business Revenue Market Share in 2016
Table Johnson＆Johnson Basic Information List
Table Cardiovascular Disease Drugs Business Revenue (Million USD) of Johnson＆Johnson (2012-2017)
Figure Johnson＆Johnson Cardiovascular Disease Drugs Business Revenue Market Share in 2016
Table Pfizer Basic Information List
Table Cardiovascular Disease Drugs Business Revenue (Million USD) of Pfizer (2012-2017)
Figure Pfizer Cardiovascular Disease Drugs Business Revenue Market Share in 2016
Table Sanofi Basic Information List
Table Cardiovascular Disease Drugs Business Revenue (Million USD) of Sanofi (2012-2017)
Figure Sanofi Cardiovascular Disease Drugs Business Revenue Market Share in 2016
Table Merck Basic Information List
Table Cardiovascular Disease Drugs Business Revenue (Million USD) of Merck (2012-2017)
Figure Merck Cardiovascular Disease Drugs Business Revenue Market Share in 2016
Table Daiichi Sankyo Company Limited Basic Information List
Table Cardiovascular Disease Drugs Business Revenue (Million USD) of Daiichi Sankyo Company Limited (2012-2017)
Figure Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Business Revenue Market Share in 2016
Table Novartis Basic Information List
Table Cardiovascular Disease Drugs Business Revenue (Million USD) of Novartis (2012-2017)
Figure Novartis Cardiovascular Disease Drugs Business Revenue Market Share in 2016
Table Bayer Basic Information List
Table Cardiovascular Disease Drugs Business Revenue (Million USD) of Bayer (2012-2017)
Figure Bayer Cardiovascular Disease Drugs Business Revenue Market Share in 2016
Table Takeda Pharmaceutical Basic Information List
Table Cardiovascular Disease Drugs Business Revenue (Million USD) of Takeda Pharmaceutical (2012-2017)
Figure Takeda Pharmaceutical Cardiovascular Disease Drugs Business Revenue Market Share in 2016
Table Hoffmann-La Roche Basic Information List
Table Cardiovascular Disease Drugs Business Revenue (Million USD) of Hoffmann-La Roche (2012-2017)
Figure Hoffmann-La Roche Cardiovascular Disease Drugs Business Revenue Market Share in 2016
Table United Therapeutics Corporation Basic Information List
Table Cardiovascular Disease Drugs Business Revenue (Million USD) of United Therapeutics Corporation (2012-2017)
Figure United Therapeutics Corporation Cardiovascular Disease Drugs Business Revenue Market Share in 2016
Table Actelion Pharmaceuticals Basic Information List
Table Cardiovascular Disease Drugs Business Revenue (Million USD) of Actelion Pharmaceuticals (2012-2017)
Figure Actelion Pharmaceuticals Cardiovascular Disease Drugs Business Revenue Market Share in 2016
Table Boehringer Ingelheim Basic Information List
Table Cardiovascular Disease Drugs Business Revenue (Million USD) of Boehringer Ingelheim (2012-2017)
Figure Boehringer Ingelheim Cardiovascular Disease Drugs Business Revenue Market Share in 2016
Table Astellas Pharma Basic Information List
Table Cardiovascular Disease Drugs Business Revenue (Million USD) of Astellas Pharma (2012-2017)
Figure Astellas Pharma Cardiovascular Disease Drugs Business Revenue Market Share in 2016
Table Global Cardiovascular Disease Drugs Market Size (Million USD) by Type (2012-2017)
Figure Global Cardiovascular Disease Drugs Market Size Share by Type in 2012
Figure Global Cardiovascular Disease Drugs Market Size Share by Type in 2013
Figure Global Cardiovascular Disease Drugs Market Size Share by Type in 2014
Figure Global Cardiovascular Disease Drugs Market Size Share by Type in 2015
Figure Global Cardiovascular Disease Drugs Market Size Share by Type in 2016
Figure Global Cardiovascular Disease Drugs Market Size Share by Type in 2017
Table Global Cardiovascular Disease Drugs Market Size (Million USD) by Application (2012-2017)
Figure Global Cardiovascular Disease Drugs Market Size (Million USD) by Application in 2012
Figure Global Cardiovascular Disease Drugs Market Size (Million USD) by Application in 2013
Figure Global Cardiovascular Disease Drugs Market Size (Million USD) by Application in 2014
Figure Global Cardiovascular Disease Drugs Market Size (Million USD) by Application in 2015
Figure Global Cardiovascular Disease Drugs Market Size (Million USD) by Application in 2016
Figure Global Cardiovascular Disease Drugs Market Size (Million USD) by Application in 2017
Table Top Consumer/End Users of Cardiovascular Disease Drugs
Figure United States Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table United States Cardiovascular Disease Drugs Market Size (Million USD) by Players (2012-2017)
Figure United States Cardiovascular Disease Drugs Market Size Share by Players in 2016
Figure United States Cardiovascular Disease Drugs Market Size Share by Players in 2017
Figure EU Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table EU Cardiovascular Disease Drugs Market Size (Million USD) by Players (2012-2017)
Figure EU Cardiovascular Disease Drugs Market Size Share by Players in 2016
Figure EU Cardiovascular Disease Drugs Market Size Share by Players in 2017
Figure Japan Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table Japan Cardiovascular Disease Drugs Market Size (Million USD) by Players (2012-2017)
Figure Japan Cardiovascular Disease Drugs Market Size Share by Players in 2016
Figure Japan Cardiovascular Disease Drugs Market Size Share by Players in 2017
Figure China Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table China Cardiovascular Disease Drugs Market Size (Million USD) by Players (2012-2017)
Figure China Cardiovascular Disease Drugs Market Size Share by Players in 2016
Figure China Cardiovascular Disease Drugs Market Size Share by Players in 2017
Figure India Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table India Cardiovascular Disease Drugs Market Size (Million USD) by Players (2012-2017)
Figure India Cardiovascular Disease Drugs Market Size Share by Players in 2016
Figure India Cardiovascular Disease Drugs Market Size Share by Players in 2017
Figure Southeast Asia Cardiovascular Disease Drugs Market Size (Million USD) and Growth Rate by Regions (2012-2017)
Table Southeast Asia Cardiovascular Disease Drugs Market Size (Million USD) by Players (2012-2017)
Figure Southeast Asia Cardiovascular Disease Drugs Market Size Share by Players in 2016
Figure Southeast Asia Cardiovascular Disease Drugs Market Size Share by Players in 2017
Figure Global Cardiovascular Disease Drugs Market Size (Million USD) by Regions (2017-2022)
Table Global Cardiovascular Disease Drugs Market Size (Million USD) by Regions (2017-2022)
Figure Global Cardiovascular Disease Drugs Market Size Share by Regions in 2017
Figure Global Cardiovascular Disease Drugs Market Size Share by Regions in 2022
Figure United States Cardiovascular Disease Drugs Revenue (Million USD) and Growth Rate (2017-2022)
Figure EU Cardiovascular Disease Drugs Revenue (Million USD) and Growth Rate (2017-2022)
Figure Japan Cardiovascular Disease Drugs Revenue (Million USD) and Growth Rate (2017-2022)
Figure China Cardiovascular Disease Drugs Revenue (Million USD) and Growth Rate (2017-2022)
Figure India Cardiovascular Disease Drugs Revenue (Million USD) and Growth Rate (2017-2022)
Figure Southeast Asia Cardiovascular Disease Drugs Revenue (Million USD) and Growth Rate (2017-2022)
Table Global Cardiovascular Disease Drugs Market Size (Million USD) by Type (2017-2022)
Figure Global Cardiovascular Disease Drugs Market Size Share by Type in 2017
Figure Global Cardiovascular Disease Drugs Market Size Share by Type in 2022
Table Global Cardiovascular Disease Drugs Market Size (Million USD) by Application (2017-2022)
Figure Global Cardiovascular Disease Drugs Market Size (Million USD) by Application in 2017
Figure Global Cardiovascular Disease Drugs Market Size (Million USD) by Application in 2022